Arch Oncology, Inc., a Brisbane, CA-based clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, raised $50m in Series B financing.
The round was led by new investor Lightchain (Scottrade Founder and former CEO Rodger Riney’s family office), with participation from existing investors RiverVest Venture Partners, Roche Venture Fund, and 3×5 Partners.
The company plans to use the proceeds to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.
Led by Julie M. Cherrington, Ph.D., President and Chief Executive Officer, Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of antibody therapies for the treatment of patients with cancer. The company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Arch Oncology’s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies.
The company has research facilities in St. Louis, MO.